Entheon Biomedical's Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US
HaluGen Life Sciences’ test evaluates an individual’s overall sensitivity and risk profile associated with psychedelic-assisted therapy
Vancouver, British Columbia–(Newsfile Corp. – June 10, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced its Psychedelics Genetic Test Kit, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc. (“HaluGen”), is now available for sale in the United States.
Who we are
Entheon is in a unique position to challenge the narrative – and expectations – around addiction recovery.
Leveraging emerging bio-technology, we are pioneering a leading-edge addiction recovery solution that harnesses the therapeutic potential of patient-centric psychedelic medicine to remedy the underlying causes of Substance Use Disorder. Focusing primarily on the powerful DMT molecule, Entheon exists to invert the addiction recovery ratio, turning the ‘untreatable case’ and ‘lost cause’ from the norm to the exception.
Learn More About Entheon
Investors
